Silo Pharma Inc, a London-headquartered biotech firm, has made significant progress in its plans to list on the NASDAQ stock exchange. The move comes after the company filed its Form S-3 registration statement with the US Securities and Exchange Commission (SEC) on 24 July.
The filing marks an important milestone for Silo Pharma as it seeks to raise capital to fuel its growth and expansion plans, particularly in Europe. According to a source close to the matter, the company is eyeing strategic partnerships and collaborations with major pharmaceutical players in the region.
Silo Pharma has been making waves in the biotech industry with its cutting-edge research in developing innovative treatments for complex neurological disorders and cancer. The company's pipeline of promising therapies has garnered significant attention from investors and analysts alike, with some predicting a strong IPO performance.
The US listing is expected to provide Silo Pharma with access to a vast pool of capital and expertise, enabling the company to accelerate its research and development efforts. While the company remains tight-lipped about specific fundraising targets, industry insiders expect the IPO to raise several hundred million dollars.
Analysts point out that the European market offers immense opportunities for growth, driven by an aging population and a rising demand for healthcare services. Silo Pharma's expansion plans are seen as a shrewd move to tap into this vast potential.